# Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)

> **NCT07314905** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Unity Health Toronto** · enrollment: 264 (estimated)

## Conditions studied

- Influenza A
- Influenza B
- SAR-CoV-2
- Acute Respiratory Infections (ARIs)

## Interventions

- **DRUG:** Baloxavir
- **DRUG:** Placebo Control

## Key facts

- **NCT ID:** NCT07314905
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-02
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-04-24
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07314905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07314905, "Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07314905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*